A5088249478- CAR-T cell therapy research
- Biosimilars and Bioanalytical Methods
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- Endometrial and Cervical Cancer Treatments
- Protein Degradation and Inhibitors
- Biomedical Ethics and Regulation
- Nanowire Synthesis and Applications
- Genetic factors in colorectal cancer
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Cancer-related Molecular Pathways
- Renal Transplantation Outcomes and Treatments
- Pancreatic and Hepatic Oncology Research
- Chromatin Remodeling and Cancer
- Lung Cancer Treatments and Mutations
- Sarcoma Diagnosis and Treatment
- Systemic Lupus Erythematosus Research
- Epilepsy research and treatment
- Ovarian cancer diagnosis and treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Breast Cancer Treatment Studies
- Cytokine Signaling Pathways and Interactions
Clinica Universidad de Navarra
2019-2024
Hospital Universitario 12 De Octubre
2024
Hospital Universitario Ramón y Cajal
2024
Navarre Institute of Health Research
2021-2022
Identification of new markers associated with long-term efficacy in patients treated CAR T cells is a current medical need, particularly diseases such as multiple myeloma. In this study, we address the impact density on functionality BCMA cells. Functional and transcriptional studies demonstrate that high expression construct show an increased tonic signaling up-regulation exhaustion vitro cytotoxicity but decrease vivo BM infiltration. Characterization gene regulatory networks using...
Mismatch repair deficiency (MMRD) is involved in the initiation of both hereditary and sporadic tumors. MMRD has been extensively studied colorectal cancer endometrial cancer, but not so other tumors, such as ovarian carcinoma. We have determined expression mismatch proteins a large cohort 502 early-stage epithelial carcinoma entailing all 5 main subtypes: high-grade serous carcinoma, endometrioid (EOC), clear cell (CCC), mucinous low-grade association with clinicopathologic...
Endometrioid ovarian carcinoma (EOC) has clinical and biological differences compared with other histologic types of carcinomas, but it shares morphologic molecular features endometrioid endometrial carcinoma. To analyze the heterogeneity EOC according to new classification cancer evaluate prognostic significance this classification, we have analyzed 166 early-stage by immunohistochemistry for mismatch repair proteins p53 expression, Sanger sequencing exonuclease domain polymerase epsilon (...
High grade colorectal carcinomas (HG-CRCs), which comprise 15% of carcinomas, are underrepresented in reported molecular studies. Clinicopathological, immunohistochemical, and features 40 HG-CRCs described. Moreover, glandular solid areas 25 tumors were separately analyzed. The expression MLH1, PMS2, MSH2, MSH6, p53, E-cadherin, CDX2, CK20, CD8, PDL1, PAN-TRK, c-MET, SMARCB1, ARID1A, SMARCA2, SMARCA4 was analyzed by immunohistochemistry. Promoter MLH1 methylation with MLH1/PMS2 loss....
ABSTRACT Identification of new markers associated with long-term efficacy in patients treated CAR T cells is a current medical need, particularly diseases such as multiple myeloma. In this study we address the impact density on functionality BCMA-CAR cells. Functional and transcriptional studies demonstrate that high expression construct show an increased tonic signaling upregulation exhaustion markers, vitro cytotoxicity but decrease vivo BM infiltration. Characterization Gene Regulatory...
ABSTRACT Hematological toxicity is a common side effect of CAR-T therapies, being particularly severe in relapsed/refractory multiple myeloma (MM) patients. In this study, we analyzed cohort 48 patients treated with BCMA cells to characterize the kinetics cytopenia, identify predictive factors and determine potential mechanism underlying these toxicities. The overall incidence cytopenia was 95.74%, grade>3 thrombocytopenia neutropenia one month after infusion observed 57% 53% still...
Delirium with refractory agitation is a common indication for palliative sedation. Significant distress and suffering can be experienced by patients, relatives caregivers when conventional sedation strategies fail in end-of-life situations. We present case report of cancer patient where the use propofol treatment hyperactive delirium to midazolam was rapidly effective, illustrating relevance managing created this challenging clinical scenario care setting. Despite fact that suboptimal...